We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of IVERIC bio, Inc. (“IVERIC” or the “Company”) (NASDAQ: ISEE), in connection with its proposed acquisition by Astellas Pharma Inc.  Under the merger agreement, the Company’s shareholders will receive $40.00 in cash for each share of IVERIC owned.  The transaction is valued at approximately $5.9 billion.

Weiss Law is investigating whether (i) IVERIC’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the $40.00 per share merger consideration adequately compensates IVERIC’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.